In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

There’s no data from a head-to-head trial directly comparing Eli ... drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be better at achieving weight loss.

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.